DRP™ Companion Diagnostic

The Drug Response Predictor (DRP™) technology leverages proprietary systems biology analytics and a big-data algorithm, combined with transcriptomic expression profiling (mRNA), to generate a drug-specific DRP companion diagnostic (CDx).  This clinically validated diagnostic identifies those patients who are likely to respond to and benefit from a given drug. (learn more)

Each of our pipeline products has a drug-specific DRP CDx, which will be used for patient selection in focused Phase 2 studies. We expect that use of the DRP will lead to significantly improved response rates versus previously conducted clinical trials conducted without a CDx. Clinical success in these planned Phase 2 studies could position us to file for accelerated regulatory approval for our pipeline products. We look forward to data from these planned clinical trials by year-end 2018.

DRP™ is a trademark of  Medical Prognosis Institute A/S.